Gain Therapeutics (GANX) Shares Outstanding (2020 - 2026)

Gain Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $42.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 47.81% year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $42.5 million (up 47.81% YoY), while the FY2025 annual figure was $33.0 million, up 21.51% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $42.5 million, up from $33.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $42.5 million in Q1 2026, with the low at $11.9 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $18.0 million (2024), against an average of $21.1 million.
• Peak annual rise in Shares Outstanding (Entity) reached 144.07% in 2022, while the deepest fall reached 0.0% in 2022.
• Gain Therapeutics' Shares Outstanding (Entity) stood at $11.9 million in 2022, then gained by 9.49% to $13.0 million in 2023, then soared by 108.53% to $27.1 million in 2024, then climbed by 21.51% to $33.0 million in 2025, then climbed by 28.88% to $42.5 million in 2026.
• Business Quant data shows GANX's Shares Outstanding (Entity) at $42.5 million in Q1 2026, $33.0 million in Q4 2025, and $36.0 million in Q3 2025.